Cargando…

Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma

Hepatocellular carcinoma (HCC) located in the caudate lobe (caudate HCC) is rare; however, patients with this type of tumour have poorer prognoses than those with HCC in other segments. Despite many published reports on the clinical usefulness of proton beam therapy (PBT) for HCC, data on the clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Iizumi, Takashi, Okumura, Toshiyuki, Sekino, Yuta, Takahashi, Hiroaki, Tsai, Yu-Lun, Takizawa, Daichi, Ishida, Toshiki, Hiroshima, Yuichi, Nakamura, Masatoshi, Shimizu, Shosei, Saito, Takashi, Numajiri, Haruko, Mizumoto, Masashi, Nakai, Kei, Sakurai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273797/
https://www.ncbi.nlm.nih.gov/pubmed/34036362
http://dx.doi.org/10.1093/jrr/rrab040
_version_ 1783721440915226624
author Iizumi, Takashi
Okumura, Toshiyuki
Sekino, Yuta
Takahashi, Hiroaki
Tsai, Yu-Lun
Takizawa, Daichi
Ishida, Toshiki
Hiroshima, Yuichi
Nakamura, Masatoshi
Shimizu, Shosei
Saito, Takashi
Numajiri, Haruko
Mizumoto, Masashi
Nakai, Kei
Sakurai, Hideyuki
author_facet Iizumi, Takashi
Okumura, Toshiyuki
Sekino, Yuta
Takahashi, Hiroaki
Tsai, Yu-Lun
Takizawa, Daichi
Ishida, Toshiki
Hiroshima, Yuichi
Nakamura, Masatoshi
Shimizu, Shosei
Saito, Takashi
Numajiri, Haruko
Mizumoto, Masashi
Nakai, Kei
Sakurai, Hideyuki
author_sort Iizumi, Takashi
collection PubMed
description Hepatocellular carcinoma (HCC) located in the caudate lobe (caudate HCC) is rare; however, patients with this type of tumour have poorer prognoses than those with HCC in other segments. Despite many published reports on the clinical usefulness of proton beam therapy (PBT) for HCC, data on the clinical outcomes of patients undergoing PBT for caudate HCC remain scarce. Therefore, the present study aimed to investigate the outcomes of this group of patients. Thirty patients with caudate HCC who underwent definitive PBT between February 2002 and February 2014 were retrospectively analysed. The total irradiation doses ranged from 55 to 77 (median 72.6) Gy relative biological dose. The median follow-up period was 37.5 (range, 3.0–152.0) months. The overall survival (OS) rates at one, three and five years were 86.6%, 62.8% and 46.1%, respectively. According to univariate and multivariate analyses, Child-Pugh A (P < 0.01), having a single tumour (P = 0.02) and a low serum alpha-fetoprotein level (AFP; P < 0.01) were significant factors predicting longer survival. The local control (LC) rates at one, three and five years were 100%, 85.9% and 85.9%, respectively, while the corresponding progression-free survival (PFS) rates were 65%, 27.5% and 22%, respectively. No grade 3 or worse adverse events were observed. PBT is effective and safe for the treatment of caudate HCC, and should therefore be considered a feasible option for intervention in patients with this disease.
format Online
Article
Text
id pubmed-8273797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82737972021-07-13 Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma Iizumi, Takashi Okumura, Toshiyuki Sekino, Yuta Takahashi, Hiroaki Tsai, Yu-Lun Takizawa, Daichi Ishida, Toshiki Hiroshima, Yuichi Nakamura, Masatoshi Shimizu, Shosei Saito, Takashi Numajiri, Haruko Mizumoto, Masashi Nakai, Kei Sakurai, Hideyuki J Radiat Res Oncology/Medicine Hepatocellular carcinoma (HCC) located in the caudate lobe (caudate HCC) is rare; however, patients with this type of tumour have poorer prognoses than those with HCC in other segments. Despite many published reports on the clinical usefulness of proton beam therapy (PBT) for HCC, data on the clinical outcomes of patients undergoing PBT for caudate HCC remain scarce. Therefore, the present study aimed to investigate the outcomes of this group of patients. Thirty patients with caudate HCC who underwent definitive PBT between February 2002 and February 2014 were retrospectively analysed. The total irradiation doses ranged from 55 to 77 (median 72.6) Gy relative biological dose. The median follow-up period was 37.5 (range, 3.0–152.0) months. The overall survival (OS) rates at one, three and five years were 86.6%, 62.8% and 46.1%, respectively. According to univariate and multivariate analyses, Child-Pugh A (P < 0.01), having a single tumour (P = 0.02) and a low serum alpha-fetoprotein level (AFP; P < 0.01) were significant factors predicting longer survival. The local control (LC) rates at one, three and five years were 100%, 85.9% and 85.9%, respectively, while the corresponding progression-free survival (PFS) rates were 65%, 27.5% and 22%, respectively. No grade 3 or worse adverse events were observed. PBT is effective and safe for the treatment of caudate HCC, and should therefore be considered a feasible option for intervention in patients with this disease. Oxford University Press 2021-05-25 /pmc/articles/PMC8273797/ /pubmed/34036362 http://dx.doi.org/10.1093/jrr/rrab040 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oncology/Medicine
Iizumi, Takashi
Okumura, Toshiyuki
Sekino, Yuta
Takahashi, Hiroaki
Tsai, Yu-Lun
Takizawa, Daichi
Ishida, Toshiki
Hiroshima, Yuichi
Nakamura, Masatoshi
Shimizu, Shosei
Saito, Takashi
Numajiri, Haruko
Mizumoto, Masashi
Nakai, Kei
Sakurai, Hideyuki
Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title_full Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title_fullStr Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title_full_unstemmed Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title_short Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
title_sort long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
topic Oncology/Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273797/
https://www.ncbi.nlm.nih.gov/pubmed/34036362
http://dx.doi.org/10.1093/jrr/rrab040
work_keys_str_mv AT iizumitakashi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT okumuratoshiyuki longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT sekinoyuta longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT takahashihiroaki longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT tsaiyulun longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT takizawadaichi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT ishidatoshiki longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT hiroshimayuichi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT nakamuramasatoshi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT shimizushosei longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT saitotakashi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT numajiriharuko longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT mizumotomasashi longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT nakaikei longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma
AT sakuraihideyuki longtermclinicaloutcomesofpatientsreceivingprotonbeamtherapyforcaudatelobehepatocellularcarcinoma